A detailed history of Verition Fund Management LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 4,000 shares of MDGL stock, worth $849,720. This represents 0.01% of its overall portfolio holdings.

Number of Shares
4,000
Previous 4,000 -0.0%
Holding current value
$849,720
Previous $1.07 Million 4.87%
% of portfolio
0.01%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$171.37 - $283.23 $4,969 - $8,213
-29 Reduced 0.72%
4,000 $1.07 Million
Q4 2023

Feb 14, 2024

BUY
$120.4 - $237.13 $3,491 - $6,876
29 Added 0.73%
4,029 $932,000
Q3 2023

Nov 14, 2023

SELL
$146.04 - $225.78 $190,144 - $293,965
-1,302 Reduced 24.56%
4,000 $584,000
Q2 2023

Aug 14, 2023

BUY
$203.88 - $312.0 $66,261 - $101,400
325 Added 6.53%
5,302 $1.22 Million
Q1 2023

May 15, 2023

BUY
$231.06 - $307.08 $646,505 - $859,209
2,798 Added 128.41%
4,977 $1.21 Million
Q4 2022

Feb 14, 2023

SELL
$58.39 - $296.54 $142,588 - $724,150
-2,442 Reduced 52.85%
2,179 $632,000
Q3 2022

Nov 14, 2022

SELL
$60.57 - $79.51 $43,549 - $57,167
-719 Reduced 13.46%
4,621 $300,000
Q2 2022

Aug 15, 2022

BUY
$58.04 - $100.2 $309,933 - $535,068
5,340 New
5,340 $382,000
Q3 2021

Nov 15, 2021

SELL
$78.35 - $105.02 $220,555 - $295,631
-2,815 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$97.2 - $137.59 $273,618 - $387,315
2,815 New
2,815 $274,000
Q1 2020

May 15, 2020

SELL
$66.76 - $93.49 $160,891 - $225,310
-2,410 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$84.28 - $118.5 $42,814 - $60,198
-508 Reduced 17.41%
2,410 $220,000
Q3 2019

Nov 14, 2019

BUY
$84.4 - $106.53 $246,279 - $310,854
2,918 New
2,918 $252,000
Q4 2018

Feb 14, 2019

SELL
$94.77 - $215.54 $174,282 - $396,378
-1,839 Closed
0 $0
Q3 2018

Nov 15, 2018

BUY
$207.3 - $300.31 $381,224 - $552,270
1,839 New
1,839 $394,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $3.63B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.